How many drugs treat Female genital tract infection?

Drug Landscape tracks 10 marketed treatments for Female genital tract infection (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/female-genital-tract-infection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Female genital tract infection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Female genital tract infection (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Female genital tract infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Invanz	ERTAPENEM	Merck & Co.	Penem Antibacterial		2001-01-01
ALATROFLOXACIN	ALATROFLOXACIN	Pfizer	alatrofloxacin		1997-01-01
Azactam	AZTREONAM	Bristol-Myers Squibb	Monobactam Antibacterial [EPC]		1986-01-01
Unasyn	SULBACTAM	Pfizer	beta Lactamase Inhibitor	Serine beta-lactamase-like protein LACTB, mitochondrial	1986-01-01
Primaxin	CILASTATIN	Merck & Co.	Renal Dehydropeptidase Inhibitor	Dipeptidase 1	1985-01-01
Primaxin	IMIPENEM	Merck Sharp & Dohme B.V.	imipenem		1985-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Claforan	CEFOTAXIME	Sterimax	Cephalosporin Antibacterial		1981-01-01
Cephalotin	cefalotin	Eli Lilly	cefalotin	Solute carrier family 22 member 8	1974-01-01
Unasyn	AMPICILLIN	Bristol-Myers Squibb	Penicillin-class Antibacterial	Transient receptor potential cation channel subfamily M member 4	1965-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 5 drugs in Female genital tract infection
Bristol-Myers Squibb · 2 drugs in Female genital tract infection
Pfizer · 2 drugs in Female genital tract infection
Merck & Co. · 2 drugs in Female genital tract infection
Eli Lilly · 1 drug in Female genital tract infection
Generic (originally Roche) · 1 drug in Female genital tract infection
Merck Sharp & Dohme B.V. · 1 drug in Female genital tract infection
Sterimax · 1 drug in Female genital tract infection
University of Oslo · 1 drug in Female genital tract infection
Assistance Publique - Hôpitaux de Paris · 1 drug in Female genital tract infection
Baxter · 1 drug in Female genital tract infection
Centre Hospitalier Universitaire Vaudois · 1 drug in Female genital tract infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Female genital tract infection:

Cite this brief

Drug Landscape (2026). Female genital tract infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/female-genital-tract-infection. Accessed 2026-06-10.

Female genital tract infection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing